Treatment with bevacizumab plus carboplatin for recurrent malignant glioma

Neurosurgery

Volumn 67, Issue 1, 2010, Pages 87-93

  Thompson, Eric M ^a   Dosa, Edit ^b   Kraemer, Dale F ^c   Neuwelt, Edward A ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Bevacizumab; Carboplatin; Imaging response; Recurrent malignant glioma; Toxicity

Indexed keywords

BEVACIZUMAB; CARBOPLATIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; GLIOBLASTOMA; HUMAN; HYPONATREMIA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CARBOPLATIN; DRUG THERAPY, COMBINATION; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RETROSPECTIVE STUDIES;

EID: 77954129869     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1227/01.NEU.0000370918.51053.BC     Document Type: Article

References (32)

1. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999; 17(8):2572-2578.
2. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy T F. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006; 66(8):1258-1260.
3. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13(4):1253-1259.
4. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinote-can for recurrent high-grade glial tumors. Cancer. 2008;112(10):2267- 2273.
5. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007;25(30):4722-4729. (Pubitemid 350086473)
6. Rich JN, Desjardins A, Sathornsumetee S, et al. Phase II study of bevzcizumab and etoposide in patients with recurrent malignant glioma. J Clin Oncol. 2008; 26(15S):94S.
7. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162-170.
8. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
9. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335-345.
10. Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R. Expression of VEGF and its receptors in different brain tumors. Neurol Res. 2005;27(4):371-377.
11. Warnick RE, Prados MD, Mack EE, et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neurooncol. 1994;19(1):69-74.
12. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol. 1991;9(5):860-864.
13. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173-180.
14. Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA. Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neuro Oncol. 2009;11(2):142-150.
15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
16. CTEP. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006.
17. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960; 20(1):37-46.
18. Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37(5):360-363.
19. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23):2335-2342.
20. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542- 2550.
21. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
22. Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009;11(5):550-555.
23. Kang TY, Jin T, Elinzano H, Peereboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. J Neurooncol. 2008;89(1):113-118.
24. Micromedix. Carboplatin. http://www.thomsonhc.com/hcs/librarian/ND-T/HCS/ ND-PR/Main/CS/619264/DUPLICATIONSHIELDSYNC/531B40/ND-PG/PRIH/ND-B/HCS/SBK/1/ ND-P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/107100/ ContentSetId/100/SearchTerm/carboplatin/SearchOption/BeginWith. Accessed August 21, 2009.
25. Micromedix. Irinotecan. http://www.thomsonhc.com/hcs/librarian/ND-T/HCS/ ND-PR/Main/CS/619264/DUPLICATIONSHIELDSYNC/531B40/ND-PG/PRIH/ND-B/HCS/SBK/3/ ND-P/Main/PFActionId/hcs.common.RetrieveDocumentCommon/DocId/923686/ ContentSetId/100/SearchTerm/irinotecan/SearchOption/BeginWith. Accessed August 21, 2009.
26. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
27. Raymond E, Brandes AA, Dittrich C, et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J Clin Oncol. 2008;26(28):4659-4665.
28. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11(1):83-95.
29. Weinstein JS, Varallyay CG, Dosa E, et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab. 2010;30:15-35.
30. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453-461.
31. Gahramanov S, Raslan A, Muldoon LL et al. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol versus gadoteridol: A pilot study. Int J Radiat Oncol Biol Phys. 2010 Apr 13. Epub ahead of print.
32. Varallyay CG, Muldoon LL, Gahramanov S, et al. Dynamic MRI using iron oxide nanoparticles to assess early vascular effects of antiangiogenic versus corticosteroid treatment in a glioma model. J Cereb Blood Flow Metab. 2009;29(4):853-860.